These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21046167)

  • 1. Successful treatment and clearing of circulating CD19-positive cells by rituximab in a child with idiopathic membranous nephropathy.
    Zhu B; Huang J
    Pediatr Nephrol; 2011 Apr; 26(4):637-8. PubMed ID: 21046167
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab in membranous nephropathy: is it a first-line treatment?
    Appel GB
    J Am Soc Nephrol; 2012 Aug; 23(8):1280-2. PubMed ID: 22797189
    [No Abstract]   [Full Text] [Related]  

  • 3. Plasmapheresis combined with rituximab for refractory idiopathic membranous nephropathy.
    Wen M; Küchle C; Sarkar O; Renders L; Heemann U; Schmaderer C
    Int Urol Nephrol; 2014 Apr; 46(4):847-8. PubMed ID: 24585365
    [No Abstract]   [Full Text] [Related]  

  • 4. Rituximab for membranous nephropathy and immune disease: less might be enough.
    Ruggenenti P; Cravedi P; Remuzzi G
    Nat Clin Pract Nephrol; 2009 Feb; 5(2):76-7. PubMed ID: 19048001
    [No Abstract]   [Full Text] [Related]  

  • 5. Successful therapeutic use of rituximab in refractory membranous glomerulonephritis.
    Cobo M; Hernández D; Rodriguez C; Pérez-Tamajón L
    Clin Nephrol; 2006 Jul; 66(1):54-7. PubMed ID: 16878436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab in primary membranous nephropathy: beyond a B-cell-centered paradigm?
    Esposito P; Grosjean F; Mangione F; Domenech MV; Rampino T
    Clin Exp Nephrol; 2018 Feb; 22(1):208-209. PubMed ID: 28660444
    [No Abstract]   [Full Text] [Related]  

  • 7. Membranous nephropathy: the start of a paradigm shift.
    Herrmann SM; Sethi S; Fervenza FC
    Curr Opin Nephrol Hypertens; 2012 Mar; 21(2):203-10. PubMed ID: 22240444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab in primary membranous nephropathy: first-line therapy, why not?
    Cravedi P; Remuzzi G; Ruggenenti P
    Nephron Clin Pract; 2014; 128(3-4):261-9. PubMed ID: 25427622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.
    Fervenza FC; Abraham RS; Erickson SB; Irazabal MV; Eirin A; Specks U; Nachman PH; Bergstralh EJ; Leung N; Cosio FG; Hogan MC; Dillon JJ; Hickson LJ; Li X; Cattran DC;
    Clin J Am Soc Nephrol; 2010 Dec; 5(12):2188-98. PubMed ID: 20705965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab treatment of idiopathic membranous nephropathy.
    Fervenza FC; Cosio FG; Erickson SB; Specks U; Herzenberg AM; Dillon JJ; Leung N; Cohen IM; Wochos DN; Bergstralh E; Hladunewich M; Cattran DC
    Kidney Int; 2008 Jan; 73(1):117-25. PubMed ID: 17943078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in idiopathic membranous nephropathy.
    Ruggenenti P; Cravedi P; Chianca A; Perna A; Ruggiero B; Gaspari F; Rambaldi A; Marasà M; Remuzzi G
    J Am Soc Nephrol; 2012 Aug; 23(8):1416-25. PubMed ID: 22822077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Ormond Disease and Idiopathic Membranous Glomerulonephritis by using Rituximab.
    Dedinská I; Svetlík D; Adamicova K; Machalekova K; Makovicky P; Jezikova A; Laca L; Miklusica J; Galajda P; Mokan M
    Iran J Kidney Dis; 2016 Sep; 10(5):332-335. PubMed ID: 27721233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab.
    Guiard E; Karras A; Plaisier E; Duong Van Huyen JP; Fakhouri F; Rougier JP; Noel LH; Callard P; Delahousse M; Ronco P
    Clin J Am Soc Nephrol; 2011 Jul; 6(7):1609-16. PubMed ID: 21700823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Helper T Cells in Idiopathic Membranous Nephropathy.
    Zhao Q; Dai H; Liu X; Jiang H; Liu W; Feng Z; Zhang N; Gao Y; Dong Z; Zhou X; Du J; Zhang N; Rui H; Yuan L; Liu B
    Front Immunol; 2021; 12():665629. PubMed ID: 34093559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy.
    Cravedi P; Ruggenenti P; Sghirlanzoni MC; Remuzzi G
    Clin J Am Soc Nephrol; 2007 Sep; 2(5):932-7. PubMed ID: 17702725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab in immunologic glomerular diseases.
    Ejaz AA; Asmar A; Alsabbagh MM; Ahsan N
    MAbs; 2012; 4(2):198-207. PubMed ID: 22377738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified neonatal B-cell repertoire as a consequence of rituximab administration to a pregnant woman.
    Martínez-Martínez MU; Baranda-Cándido L; González-Amaro R; Pérez-Ramírez O; Abud-Mendoza C
    Rheumatology (Oxford); 2013 Feb; 52(2):405-6. PubMed ID: 22772325
    [No Abstract]   [Full Text] [Related]  

  • 18. B cell suppression in primary glomerular disease.
    Rood IM; Hofstra JM; Deegens JK; Wetzels JF
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):166-81. PubMed ID: 24602466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody.
    Dahan K; Johannet C; Esteve E; Plaisier E; Debiec H; Ronco P
    Kidney Int; 2019 Jan; 95(1):233-234. PubMed ID: 30606419
    [No Abstract]   [Full Text] [Related]  

  • 20. Rituximab In The Treatment Of Refractory Idiopathic Membranous Nephropathy In Pakistani Population.
    Anjum N; Nabi Z; Alam MA
    J Ayub Med Coll Abbottabad; 2019; 31(2):265-268. PubMed ID: 31094128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.